Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

Mihai Gheorghiade, Ami N. Shah, Muthiah Vaduganathan, Javed Butler, Robert O. Bonow, Giuseppe M C Rosano, Scott Taylor, Stuart Kupfer, Frank Misselwitz, Arjun Sharma, Gregg C. Fonarow

Research output: Contribution to journalArticlepeer-review

Abstract

Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.

Original languageEnglish
Pages (from-to)285-290
Number of pages6
JournalHeart Failure Clinics
Volume9
Issue number3
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Heart failure
  • Hospitalized heart failure
  • Postdischarge mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.'. Together they form a unique fingerprint.

Cite this